Coronavirus disease 2019 (COVID-19) occurs following infection with the potentially fatal, severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) virus. Infection can be complicated by coagulopathy, at times featuring thrombocytopenia and thrombosis alongside other coagulation abnormalities, also termed COVID-19 associated coagulopathy (CAC). Data concerning CAC in pregnancy is limited. Better understanding of physician experiences is essential to identify current practice patterns and knowledge gaps.
To determine physician experiences and practice patterns regarding CAC in pregnancy.
Self-administered survey utilizing the RedCap online platform; supported by the ISTH Subcommittee on Women’s Health Issues in Thrombosis and Hemostasis.
Seventy-five respondents fully or partially completed the survey. Of 1546 reported cases, disease severity was specified in 1298. Sixty-four percent of COVID-19 infections were mild, while 4% were severe. Of all cases, 1% developed CAC, with 65% classified as severe. The most frequent abnormalities included thrombocytopenia, elevated CRP, D-dimer, and lymphopenia. Low-molecular-weight heparin was the anticoagulant of choice in CAC and was provided by 77% of respondents, with 60% using standard-prophylactic dosing. Thrombosis occurred in 7 anticoagulated patients who were receiving standard prophylactic (4) or weight-based (3) dosing. Disease severity and additional thrombosis risk factors dictated anticoagulation duration.
In the select population reported by our survey, CAC appears to be uncommon in pregnancy. Anticoagulation practices vary and may not reflect current guidelines. Venous thromboembolism was observed in some CAC patients despite prophylactic anticoagulation (including standard and weight-adjusted dosing). Urgent research is required to determine appropriate anticoagulant dosing and duration in pregnant women with COVID-19 infection.